Allarity Therapeutics, Inc. Contracts & Agreements

Employment Agreement, dated as of September 30, 2024, by and between Allarity Therapeutics, Inc., and Jeremy R. Graff (Filed With SEC on October 4, 2024)

Second Amendment to At-The-Market Issuance Sales Agreement, dated September 9, 2024 (Filed With SEC on September 13, 2024)

Employment Agreement, dated as of September 12, 2024, by and between Allarity Therapeutics, Inc., and Alexander Epshinsky (Filed With SEC on September 13, 2024)

Form of Securities Purchase Agreement between the Company and the investors thereto, dated August 19, 2024 (Filed With SEC on August 21, 2024)

Form of Registration Rights Agreement by and among the Company and the investors named therein, dated August 19, 2024 (Filed With SEC on August 21, 2024)

Sixth Amendment to Exclusive License Agreement (Filed With SEC on August 21, 2024)

Management Services Agreement, effective as of June 1, 2024 (Filed With SEC on June 6, 2024)

First Comprehensive Amendment to At-The-Market Issuance Sales Agreement, dated May 17, 2024 (Filed With SEC on May 21, 2024)

Consulting Agreement (James G. Cullem) (Filed With SEC on May 14, 2024)

Confidential Settlement Agreement and General Release (James G. Cullem) (Filed With SEC on May 14, 2024)

Fifth Certificate of Amendment to Certificate of Incorporation of Allarity Therapeutics, Inc (Filed With SEC on April 4, 2024)

At-The-Market Issuance Sales Agreement, dated March 19, 2024, by and between Allarity Therapeutics, Inc. and Ascendiant Capital Markets, LLC (Filed With SEC on March 20, 2024)

Senior Convertible Note, dated as of March 14, 2024 (Filed With SEC on March 15, 2024)

Employment Agreement (Steen Knudsen) (Filed With SEC on March 8, 2024)

Amendment Senior Convertible Notes (Filed With SEC on March 1, 2024)

Senior Convertible Note, dated as of February 13, 2024 (Filed With SEC on February 14, 2024)

Limited Waiver Agreement, dated as of February 13, 2024, by and between the Company and the Purchaser listed on the signature page attached thereto (Filed With SEC on February 14, 2024)

Amendment to Securities Purchase Agreement, dated as of January 25, 2024, by and between the Company and the Purchaser listed on the signature page attached thereto (Filed With SEC on January 25, 2024)

Senior Convertible Note (Filed With SEC on January 19, 2024)

Securities Purchase Agreement, dated as of January 18, 2024, by and between the Company and the Purchaser listed on the signature page attached thereto (Filed With SEC on January 19, 2024)

Form of Lock Up Agreement (Filed With SEC on December 15, 2023)

Form of Lock Up Agreement (Filed With SEC on December 6, 2023)

Form of Placement Agency Agreement (Filed With SEC on December 5, 2023)

Form of Pre-Funded Warrant (Filed With SEC on December 5, 2023)

Form of Series A Common Warrant (Filed With SEC on December 5, 2023)

Form of Series B Common Warrant (Filed With SEC on December 5, 2023)

Form of Securities Purchase Agreement (Filed With SEC on December 5, 2023)

Form of New Warrant (Filed With SEC on September 15, 2023)

Form of Inducement Letter (Filed With SEC on September 15, 2023)

Limited Waiver between the Company and 3i, LP (Filed With SEC on September 15, 2023)

First Amendment to Securities Purchase Agreement and Registration Rights Agreement (Filed With SEC on August 14, 2023)

Form of Amended and Restated Common Stock Purchase Warrant (Filed With SEC on July 11, 2023)

Secured Note Purchase Agreement (Filed With SEC on June 30, 2023)

Secured Promissory Note (Filed With SEC on June 30, 2023)

Security Agreement (Filed With SEC on June 30, 2023)

Form of Placement Agency Agreement (Filed With SEC on June 30, 2023)

Form of Pre-Funded Warrant (Filed With SEC on June 30, 2023)

Form of Common Warrant (Filed With SEC on June 30, 2023)

Form of Securities Purchase Agreement (Filed With SEC on June 30, 2023)

Form of Lock-Up Agreement (Filed With SEC on June 30, 2023)

Third Amendment to the Exclusive License Agreement with Eisai, Inc (Filed With SEC on June 7, 2023)

Form of Limited Waiver and Amendment Agreement (Filed With SEC on June 7, 2023)

3i, LP - Limited Waiver and Amendment Agreement (Filed With SEC on June 7, 2023)

AMENDMENT TO MODIFICATIONAND EXCHANGE AGREEMENT (Filed With SEC on June 1, 2023)

FOURTHAMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on June 1, 2023)

Form of Pre-Funded Warrant (Filed With SEC on April 25, 2023)

Form of Common Warrant (Filed With SEC on April 25, 2023)

Warrant to Purchase Common Stock (Filed With SEC on April 25, 2023)

Securities Purchase Agreement (Filed With SEC on April 25, 2023)

Secured Promissory Note (Filed With SEC on April 25, 2023)

Modification and Exchange Agreement (Filed With SEC on April 25, 2023)

Cancellation of Debt Agreement (Filed With SEC on April 25, 2023)

First Amendment to Registration Rights Agreement (Filed With SEC on April 25, 2023)

Limited Waiver Agreement (Filed With SEC on April 25, 2023)

First Amendment to Secured Note Purchase Agreement (Filed With SEC on April 12, 2023)

First Amendment to Security Agreement (Filed With SEC on April 12, 2023)

Form of Secured Promissory Note (2023) (Filed With SEC on April 12, 2023)

Form of Placement Agency Agreement (Filed With SEC on March 28, 2023)

Form of Pre-Funded Warrant (Filed With SEC on March 28, 2023)

Form of Common Warrant (Filed With SEC on March 28, 2023)

Form of Securities Purchase Agreement (Filed With SEC on March 28, 2023)

Form of Lock- Up (Filed With SEC on March 28, 2023)

Description of Capital Stock (Filed With SEC on March 13, 2023)

Letter Agreement with 3i, LP (Filed With SEC on March 13, 2023)

Letter Agreement with 3i, LP dated January 23, 2023 (Filed With SEC on March 13, 2023)

Form of Securities Purchase Agreement (Filed With SEC on February 28, 2023)

Form of Registration Rights Agreement (Filed With SEC on February 28, 2023)

Limited Waiver Agreement (Filed With SEC on February 28, 2023)

Employment Agreement with James G. Cullem dated January 12, 2023 (Filed With SEC on January 19, 2023)

Employment Agreement with Joan Brown dated January 12, 2023 (Filed With SEC on January 19, 2023)

Separation Agreement with Steve Carchedi (Filed With SEC on October 7, 2022)

Separation Agreement with Jens Knudsen (Filed With SEC on October 7, 2022)

Second Amendment to Development, Option & License Agreement (Filed With SEC on October 7, 2022)

Second Amendment to License Agreement (Filed With SEC on September 30, 2022)

First Amendment to Forbearance Agreement and Waiver (Filed With SEC on June 10, 2022)

Description of Capital Stock (Filed With SEC on May 17, 2022)

Assignment and Assumption Agreement between Allarity Therapeutics, Inc. and Allarity A/S (Filed With SEC on May 17, 2022)

Exclusive License Agreement with Oncoheroes Bioscience, Inc. dated January 2, 2022 (Stenoparib) (Filed With SEC on May 17, 2022)

Exclusive License Agreement with Oncoheroes Bioscience, Inc. dated January 2, 2022 (Dovitnib) (Filed With SEC on May 17, 2022)

Amended and Restated License Agreement among Allarity Therapeutics Europe ApS, LiPlasome Pharma ApS, and Chosa ApS dated March 28, 2022 (Filed With SEC on May 17, 2022)

Support Agreement between Allarity Therapeutics A/S and LiPlasome Pharma ApS, dated March 28, 2022 (Filed With SEC on May 17, 2022)

Forbearance Agreement and Waiver (Filed With SEC on May 6, 2022)

First Amendment to License Agreement (Filed With SEC on April 18, 2022)

Promissory Note (Filed With SEC on April 18, 2022)

Asset Purchase Agreement dated December 17, 2021, between Allarity Therapeutics A/S, Allarity Therapeutics, Inc. and Allarity Acquisition Subsidiary Inc (Filed With SEC on December 22, 2021)

Form of Warrant (Filed With SEC on December 15, 2021)

Employment Agreement by and between Allarity Therapeutics, Inc. and Jens E. Knudsen (Filed With SEC on December 10, 2021)

Employment Agreement by and between Allarity Therapeutics, Inc. and James G. Cullem (Filed With SEC on December 10, 2021)

Employment Agreement by and between Allarity Therapeutics, Inc. and Marie Foegh, M.D (Filed With SEC on December 10, 2021)

Amended and Restated Plan of Reorganization and Asset Purchase Agreement by and among Allarity Therapeutics, Inc. a Delaware corporation, Allarity Acquisition Subsidiary, a... (Filed With SEC on December 6, 2021)

Allarity Therapeutics, Inc. 2021 Equity Incentive Plan (Filed With SEC on December 6, 2021)

Third Amendment To Exclusive License Agreement with Smerud Medical Research International AS Dated as of September 28, 2021 (Filed With SEC on October 12, 2021)

Specimen Common Stock Certificate of Allarity Therapeutics, Inc (Filed With SEC on September 13, 2021)

First Amendment to the Exclusive License Agreement between Eisai and Allarity Therapeutics A/S dated December 20, 2020 (Filed With SEC on September 13, 2021)

Second Amendment to Exclusive License Agreement between Oncology Venture, ApS and Eisai, Inc. dated as of August 3, 2021 (Filed With SEC on September 13, 2021)

Form of Warrant (Filed With SEC on August 20, 2021)

Exclusive License Agreement between Oncology Venture A/S and Smerud Medical Research International AS Dated as of June 26, 2020 (Filed With SEC on August 20, 2021)

Amended and Restated License Agreement between Allarity Therapeutics A/S and LiPlasome Pharma ApS, dated January 2021 (Filed With SEC on August 20, 2021)

Exclusive License Agreement between Oncology Venture, APS and 2-BBB Medicines BV, dated as of March 27, 2017 (Filed With SEC on August 20, 2021)

Development, Option and License Agreement between Oncology Venture ApS and R-Pharm US Operating LLC, dated March 1, 2019 (Filed With SEC on August 20, 2021)

Exclusive License Agreement between Oncology Venture, ApS and Eisai, Inc., dated as of July 6, 2017 (Filed With SEC on August 20, 2021)

License Agreement between Novartis Pharma Ag and Oncology Venture, ApS, dated April 6, 2018 (Filed With SEC on August 20, 2021)

Securities Purchase Agreement dated May 20, 2021 between Allarity Therapeutics, Inc. and 3i, LLP (Filed With SEC on August 20, 2021)

Registration Rights Agreement dated May 20, 2021 between Allarity Therapeutics, Inc. and 3i, LLP (Filed With SEC on August 20, 2021)

Asset Purchase Agreement dated July 23, 2021 between Allarity Therapeutics A/S and Lantern Pharma Inc (Filed With SEC on August 20, 2021)

Category

Industry

Companies

Contracts

Allarity Therapeutics, Inc. Contracts & Agreements